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Abstract
Background: We determined the effect of andrographolide and one of its novel semi-synthetic
analog, DRF 3188, on the cell cycle of MCF 7 breast cancer cells.
Methods: The effect of the compounds on cell cycle was determined using FACS and western blot
analysis of cell cycle proteins. Hollow fibre assay was used to determine if the compounds had the
same effect on the cell cycle in vitro and in vivo.
Results: Our results from the in vitro and in vivo experiments show that both the compounds block
the cell cycle at the G0-G1 phase through the induction of the cell cycle inhibitor, p27, and the
concomitant decrease in the levels of Cdk4.
Conclusion:  The results show that the novel semi-synthetic analog, DRF3188, and
andrographolide bring about the anti cancer activity by a similar mechanism.
Background
Cell cycle can be defined as an ordered set of events cul-
minating in cell growth and division into two identical
daughter cells. In normal cells this complex process is ini-
tiated only in the presence of a mitogenic stimulus. Vari-
ous proteins like the cyclin dependent kinases; cyclins and
cyclin dependent kinase inhibitors regulate this event [1].
However, in cancer cells this regulation of the cell cycle is
lost and the cells continue to divide irrespective of the
presence or absence of a mitogenic stimulus [2]. This
observation has led to deciphering the mechanism of
action of many of the known anti-cancer agents, currently
in clinical use. These agents were shown to block the cell
cycle at different stages. Examples include, Methotrexate
(blocks at the S-phase), Doxurubicin (blocks at the G2
phase), Topotecan (blocks at the S and G2 phase) etc.
Intense research efforts are now on for identifying cell
cycle specific inhibitors for the treatment of cancer (Ex:
Flavopiridol).
Andrographolides, obtained from the herb Andrographis
paniculata, are known to have several medicinal properties
including anti-cancer activity [3-6]. Using androgra-
pholide (Fig. 1) as a template a library of analogs were
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synthesized and analysed for anti-cancer activity. One of
the semi-synthetic analogs, DRF 3188 (Fig. 1), [7] was
shown to have a better anti-cancer activity compared to
the parent compound (extracted from the whole plant)
[8]. We wanted to determine the effect of andrographolide
and its semi-synthetic analog on the cell cycle. In this
paper we show that andrographolide and DRF 3188 block
the cell cycle at the G0-G1 phase, both in vitro and in vivo.
This shows that the semi-synthetic analog and the parent
molecule have a similar mechanism of anticancer activity.
Methods
Drugs
Lovastatin, Andrographolide and the semi-synthetic ana-
log (DRF 3188) were synthesized by the Discovery
Research Group (synthesis and SAR of Andrographolide
and DRF3188- reference [7] and [8]). The drugs were dis-
solved in DMSO at 10-2 M concentration and then further
diluted to the required concentration in the appropriate
assay medium.
Cell culture
MCF7, breast cancer cell lines were obtained from ATCC,
USA. Cells were grown in RPMI-1640 media (Sigma, U.S.)
containing 10% FBS, 100 mg/L Streptomycin and 105
units Penicillin. A humified incubator with 5% CO2 was
used to grow the cells at 37°C.
In vitro experiments
Stable end point MTT assay
The fibres containing cells were transferred into 6 well
plates containing RPMI-1640 with 20% FBS and incu-
bated for 30 m at 37°C in a 5% CO2 incubator. 1 ml of
0.1% MTT (Sigma M2128) solution was added and incu-
bated at 37°C for 4 h in a 5% CO2 incubator. The MTT
solution was aspirated out and the fibres were washed
with 2 ml of 2.5% Protamine sulfate (Sigma P4380). A
second wash was done using 1 ml 2.5% Protamine sulfate.
The fibres were air dried for 2–3 h. 250 µl of DMSO was
added, 150 µl of each sample was transferred to a 96 well
plate and read at 570 nm. The percentage net growth of
the cells was calculated using the formula (T-To/To) × 100
where T is the O.D. 570 nm of the cells in the fibres at the
Structure of Andrographolide and the semi synthetic analog of andrographolide, DRF3188 Figure 1
Structure of Andrographolide and the semi synthetic analog of andrographolide, DRF3188
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end of the experiment and T0 is the O.D. 570 nm of the
cells at the time of loading cells into the fibre.
Flow cytometry
MCF 7 breast cancer cells were treated with 5 µM
andrographolide or DRF 3188 for 24 and 48 h. The cells
were trypsinized, washed with PBS and fixed in 80% eth-
anol overnight at 4°C. Fixed cells were washed with PBS
and 2 × 106 cells/ml were resuspended in PBS. Cells were
incubated for 10 m at 37°C with 10 µg/ml RNase and
then for a further 10 m at 4°C. Cells were stained with 500
µg/ml propidium iodide. The samples were run on a FACS
and analysed for DNA ploidy. The analysis was done
using the "cell quest" soft ware from Becton Dickinson.
Western blotting
Cells were plated and incubated at 37°C for 24 h. 25 µM
andrographolide, 25 µM Lovastatin or 5 µM DRF 3188
were added. For all experiments cells were treated with the
above mentioned concentrations of the compounds for
24 h. Lysis buffer (10 mM Tris-Cl pH7.2, 150 mM Sodium
chloride, 1% triton X-100, 0.1 mM Sodium orthovanad-
ate, 1 mM PMSF, 10 ug/ml Aprotinin, 10 ug/ml Leupep-
tin) was added to the cell pellet and stored on ice for 30 m
with intermittent vortexing. The cell lysate was centrifuged
to remove the unlysed cells. To the supernatant 3x Lae-
mmli buffer (100 mM Tris pH 6.8, 6% SDS, 0.3%
bromophenol blue, 30% glycerol and 3% β-Mercaptoeth-
anol) was added to get a final concentration of 1x. The
samples were boiled at 95°C for 5 mins and the proteins
were separated by SDS PAGE. Proteins were transferred
onto a nitrocellulose membrane by the semi-dry method.
Western blot analysis was done using p27 (sc-776), CDK
4 (sc-749), CDK 1 (sc-747), Cyclin B1 (sc-752), antibod-
ies form Santa Cruz Biotechnology Inc.; Cyclin D1
(Pharmingen, cat.# 556470) and Actin (Oncogene
research cat.# cpo1). The blots were developed using the
ECL kit from Amersham.
In vivo experiment
Hollow fiber assay
The in vivo activity of andrographolide and DRF 3188 was
determined using the modified hollow fibre assay method
[9]. Hollow fibres (from Spectrum laboratories, USA)
were rehydrated, flushed with 70% ethanol, washed and
sterilized. The fibres were loaded with 105 cells/ml, of
MCF 7, in RPMI-1640 with 20% FBS. Fibre capsules of 2
cms in length were prepared by heat sealing and incu-
bated overnight at 37°C in a humified incubator with 5%
CO2. The fibres were implanted into two compartments,
the peritoneum (IP) and subcutaneous (SC) sites of Swiss
Albino Mice (SAM). Two days after implantation the
drugs were administered intra-peritoneally at a low and
high dose (determined by the Maximum Tolerated Dose
(MTD) experiment). The compound was administered
once a day for 4 days. A day after the drug treatment
period, the animals were sacrificed by cervical dislocation
and the fibres were collected in RPMI-1640 with 20% FBS.
Cells from one fibre, from each animal, were used for MTT
assay. Cells from the remaining fibres were used for pre-
paring the lysate. The proteins were separated by SDS-
PAGE and the western blot was done using p27 and CDK
4 antibody. Equal protein loading in each lane was deter-
mined using the actin antibody.
Results
Mechanism of anti-cancer activity of andrographolide and 
DRF 3188 – In vitro studies
To determine if andrographolide and its semi-synthetic
analog show a similar effect on the cell cycle, we used flu-
orescence activated cell sorting (FACS). Cells were treated
with the compounds for 24 or 48 h and the block in the
cell cycle was determined.
The percentage increase or decrease in the number of cells
in each phase of the cell cycle compared to that in the con-
trol was determined and represented as a bar graph. On
treatment with 10 µM Lovastatin for 24 h there was a 25%
increase in the number of MCF 7 cells in the G0-G1 phase
(Figure 2A) while there was a 52% and 42.3% decrease in
the number of cells entering the G2-M and S phase of the
cell cycle, respectively. This indicated that the Lovastatin
treated cells were arrested in the G0-G1 phase of the cell
cycle. FACS analysis of MCF 7 cells treated with Butyrolac-
tone for 24 h showed a 7.5% increase in the number of
cells in the G2-M phase and a decrease in the number of
cells in the G0-G1 and S phase of the cell cycle, when com-
pared to the control cells, indicating a G2-M phase arrest.
On treatment with andrographolide or DRF 3188, for 24
h, an increase in the number of cells in the G0-G1 phase
(15–20%) and a significant decrease in the number of
cells entering the S and G2-M phase was observed (about
30% less cells in the S phase and approximately 50–60%
decrease in the G2-M phase) compared to the control
cells. This indicated that andrographolide and DRF 3188
treated MCF 7 cells were blocked in the G0-G1 phase of
the cell cycle.
When the treatment period was increased to 48 h a similar
profile was seen (Figure 2B). Andrographolide and DRF
3188 caused a G0-G1 phase cell cycle arrest as was seen in
the Lovastatin treated cells. However, a better cell cycle
arrest was seen with a 24 h drug treatment. After a 48 hour
treatment with andrographolide or DRF 3188 an
increased population of the cells were found in the sub G1
phase of the cell cycle (data not shown). This indicated
that after a prolonged exposure, to the compounds, the
cells were dying. Hence for the remaining experiments the
cells were treated with the compounds for 24 h.BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/26
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FACS experiments showed that the andrographolide and
its semi-synthetic analog block the cell cycle at the G0-G1
phase. To confirm this result we analysed the levels of cell
cycle regulatory proteins in the andrographolide and DRF
3188 treated MCF 7 cells by western blot analysis. Cells
were treated with 25 µM Lovastatin or 25 µM androgra-
pholide or 5 µM DRF 3188 for 24 h. The cell lysates were
analysed for levels of p27, Cdk 4, Cyclin D1, Cdk 1
(Cdc2p34), Cyclin B1. Equal protein loading was shown
using actin antibody.
Western blot analysis of the Lovastatin, andrographolide
or DRF 3188 treated MCF 7 cells (Figure 3A) showed an
increase in the level of the cell cycle inhibitor p27 when
compared to the levels in the control (3B). The levels of
Cdk4 decreased after treatment with the compounds (Fig.
3A,3C). Andrographolide or DRF 3188 treated MCF 7
cells did not show any significant change in the levels of
Cyclin D1 or Cyclin B1. However, on treatment with Lov-
astatin a decrease in Cyclin B1 levels was observed. The
levels of Cdk 1 (p34Cdc2) in the control and DRF 3188
treated cells were similar while a decrease was seen after
treatment with andrographolide. Lovastatin treated cells
showed a significantly reduced level of Cdk1 when com-
pared to the control cells. Western blot analysis with actin
antibody showed that similar concentration of protein
was loaded in each lane. The induction of p27 and
decrease in the Cdk4 levels indicate a G0-G1 arrest of the
cell cycle corroborating the FACS data.
Mechanism of anti-cancer activity of andrographolide and 
DRF 3188 – In vivo studies
Hollow fibre assay system was used to determine the effect
of andrographolide and DRF 3188 on MCF 7 cells, in vivo.
Mechanism of anti-cancer activity of andrographolide and DRF 3188 – In vitro studies: Cell cycle analysis Figure 2
Mechanism of anti-cancer activity of andrographolide and DRF 3188 – In vitro studies: Cell cycle analysis A. Flu-
orescence associated cell sorting analysis of MCF 7 cells treated with andrographolide (5 µM) or DRF 3188 (5 µM) for a period 
of 24 hours. Lovastatin (10 µM) and Butyrolactone (10 µM) were used as positive controls. Andrographolide and DRF 3188 
exhibit a G0-G1 arrest like Lovastatin. Butyrolactone treated MCF 7 cells exhibit a G2-M arrest. B. After a 48 h treatment 
with Andrographolide or DRF 3188 MCF7 cells exhibit a G0-G1 arrest, similar to Lovastatin. Butyrolactone treated cells 
exhibit a G2-M arrest.
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MTT assay was done to determine the cell viability after
treatment with the low and high dose of andrographolide
and it's analog. As shown in the figure 4A,
andrographolide at a concentration of 50 mg/kg body
weight did not have any effect on the cancer cells, irrespec-
tive of the site where the fibres were implanted. At the
higher concentration of 100 mg/kg body weight, growth
of about 50% of the cells (fibres placed in the peritoneum
or subcutaneous layer) was arrested. The proliferation of
about 75% of the cells placed in the peritoneum or subcu-
taneous region was affected when treated with the low or
high dose of DRF 3188.
Further, to determine if the in vivo anti-proliferative effect
of andrographolide and DRF 3188 was due to a G0-G1
cell cycle arrest, as was seen in the in vitro experiments,
MCF 7 cells placed in the hollow fibres were analysed by
western blot to determine the levels of cell cycle proteins.
Western blot analysis (Figure 4B) showed that the
andrographolide (50 mg/kg) treated cells, present in the
peritoneum (left panel) or subcutaneous region (right
panel), and the untreated control cells had similar quan-
tities of the cell cycle inhibitor p27 and the cyclin depend-
ent kinase, Cdk 4. However andrographolide treatment, at
Mechanism of anti-cancer activity of andrographolide and DRF 3188 – In vitro studies: Western blot analysis of cell cycle  proteins Figure 3
Mechanism of anti-cancer activity of andrographolide and DRF 3188 – In vitro studies: Western blot analysis of 
cell cycle proteins A. Western blot analysis of cells treated with Andrographolide (25 µM) or DRF 3188 (5 µM) for 24 
hours. An induction of the cell cycle inhibitor p27 and reduction in the levels of Cdk4 is observed. No change is observed in 
the levels of Cyclin D1, Cdk1 or Cyclin B1 in DRF 3188 treated cells. A similar effect is seen in the andrographolide treated 
cells, but a slight decrease in the level of Cdk 1 is observed. Lovastatin treated cells show decreased levels of Cdk1 and cyclin 
B1. Actin is used as the internal loading control. B) Densitometric analysis of the western blot with p27 antibody. An induction 
of p27 is seen in MCF7 cells treated with 25 uM Lovastatin (4.5 fold), 25 uM Andrographolide (3 fold) and 5 uM DRF3188 (2 
fold). C) Densitometric analysis of the western blot with Cdk4 antibody. A decrease in the levels of Cdk4 is seen when MCF7 
cells are treated with 25 uM Lovastatin (0.4 fold), 25 uM Andrographolide (0.8 fold) and 5 uM DRF3188 (0.4 fold).
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100 mg/kg body weight, resulted in an induction of p27
in the cells placed at both the sites. A decrease in the levels
of Cdk4 was seen only in the cells placed in the perito-
neum and not in the subcutaneous region.
DRF 3188 at a high and low dose caused an induction of
p27 in the MCF 7 cells placed in the peritoneum (left
panel). An increase in p27 levels was seen in the MCF 7
cells placed in the subcutaneous region (right panel)
when treated with 25 mg/kg body weight DRF3188. How-
ever at the higher dose of 50 mg/kg DRF3188 no such
Mechanism of anti-cancer activity of andrographolide and DRF 3188 – In vivo studies Figure 4
Mechanism of anti-cancer activity of andrographolide and DRF 3188 – In vivo studies. A. MTT assay of the cells 
placed in the hollow fibres and implanted either in the peritoneum (IP) or sub-cutaneous (SC) region of Swiss Albino Mice 
(SAM). Andrographolide does not have any effect on the cells at the lower dose of 50 mg/kg. However, a 50% cell kill is seen at 
the higher dose of 100 mg/kg. DRF 3188 treatment results in the death of 75% of cells after treatment with low or high dose of 
the compound. This effect is observed irrespective of whether the cells are present in the peritoneum or subcutaneous region. 
B. Western Blot analysis of the MCF 7 cells placed in the hollow fibre, after treatment for four days. At the low dose of 50 mg/
kg andrographolide has no effect on the cells placed in the peritoneum or subcutaneous layer. At the high dose of 100 mg/kg of 
andrographolide an induction of p27 is seen. Similarly treatment with low or high dose of the semi synthetic analog DRF 3188 
leads to an induction of p27. Under similar conditions cells placed in the peritoneum exhibit a reduction in the levels of Cdk 4. 
However, the cells placed in the subcutaneous region do not exhibit this effect. The western blot with Actin was done as the 
internal loading control.
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increase could be detected because of the decreased pro-
tein loading as shown by the western blot with actin. At
both the low (25 mg/kg) and high dose (50 mg/kg) a
decrease in the Cdk4 levels was seen only in the cells
placed in the peritoneum (left panel) and not in the sub-
cutaneous region (right panel). A decrease in Cdk 4 seen
when MCF 7 cells (subcutaneous) were treated with 50
mg/kg DRF 3188 was due to a loading error as was shown
by the western blot with actin antibody. Actin was used as
the internal loading control.
This result clearly showed that the andrographolide and
DRF 3188 treatment exerted a similar effect on the cell
cycle, both in vitro and in vivo.
Discussion
Andrographolide and its semi-synthetic analog, DRF
3188, are both known to have an anti-cancer and immu-
nomodulatory activity [10,11]. In this paper we show that
Andrographolide and DRF 3188 bring about the anti-can-
cer activity by blocking the cell cycle at the G0-G1 phase.
This effect of the compounds on the cell cycle is similar
both in vitro and in vivo.
Previously, Parceslain Incorporated had reported that
Andrographolides have an anti-cancer activity brought
about by reducing the levels and activity of Cdk 1, thus
indicating a G2-M arrest [12]. However, their FACS data
showed an increase in the number of cells in the G0-G1
phase and decrease in the number of cells in the G2-M
phase, indicating a G0-G1 arrest of the cell cycle. Since
their FACS and biochemical data were not corroborating
we wanted to determine the exact effect of Androgra-
pholide on the cell cycle.
FACS analysis was performed using the MCF 7 cells
treated with Andrographolide or its analog. Treatment
with either the parent compound or the analog clearly
showed that the cell cycle was arrested at the G0-G1
phase. In order to confirm this observation we checked
the levels of cell cycle proteins. It is known that specific
cyclins and cyclin dependent kinases are activated at each
stage of the cell cycle, and are degraded once their func-
tion is completed [13]. Cell cycle inhibitors, p21, p27,
p57 etc are also known to regulate the cell cycle [14].
Western blot analysis of the cells treated with androgra-
pholide or its analog showed an induction of the cell cycle
inhibitor p27. p27 is known to prevent the entry of the
cells into the 'synthetic phase' (S phase) from the G0-G1
phase [14]. p27 binds to the Cdk4-cyclin D1 complex pre-
venting phosphorylation of the retinoblastoma (Rb) pro-
tein and release of the elongation factor E2F. This prevents
the transcription of many of the proteins required for the
cell to transit the 'S' phase. Interestingly, treatment with
andrographolide or DRF 3188 resulted in a decrease in the
level of Cdk 4 but there was no significant change in the
levels of Cyclin D1. No significant change in the level of
Cdk1 was seen and the kinase activity was also not
affected (data not shown), indicating that the cells were
not blocked in the G2-M phase as reported previously
[12].
The cellular effect of andrographolide and DRF 3188 on
cancer cells is indicated by induction of p27 and decrease
in the levels of Cdk4 resulting in G0-G1 cell cycle arrest.
Next we wanted to address whether this cellular effect on
cancer cells would be similar when compounds are given
in vivo in an animal model. Hollow fibre assay offers a
unique opportunity, depending on the route of adminis-
tration, to study both the direct cellular effect of the com-
pound and the indirect effect after systemic circulation of
the compound [15]. Also the in vivo effect of the com-
pound can be determined on a pure population of cancer
cells that is not possible in the xenograft model where the
surrounding normal cells can have a contaminating effect
[16].
The hollow fibre assay showed that both andrographolide
and DRF 3188 have an anti-proliferative effect on the cells
placed in the peritoneum (direct effect) and subcutaneous
region (distant site). Western blot analysis of these cells
showed an induction in the levels of p27 indicating a G0-
G1 arrest of the cell cycle, as was seen in the in vitro exper-
iments (FACS analysis could not be done due to the fewer
number of cells used in the hollow fibre assay). This result
demonstrated that andrographolide and its novel semi-
synthetic analog have a similar effect on the cell cycle both
in vitro and in vivo.
Andrographolide and DRF 3188 block the cell cycle at the
G0-G1 phase. The simultaneous induction of p27 and
decrease in Cdk 4 suggests that the p27 might be binding
and inactivating the Cdk4 leading to its degradation.
However, one would expect a degradation of the corre-
sponding cyclin, Cyclin D1 too. However, we see no
change in the level of this protein. The decrease in the
level of Cdk4 in the presence of the compounds could be
due to a decrease in transcription of the CDK4 gene. How-
ever, we do not know if the effect on the levels of p27 and
Cdk4 seen in the andrographolide treated and DRF 3188
treated cells are interdependent or are occurring inde-
pendent of each other. To understand the mechanism bet-
ter we are currently trying to determine the exact
molecular target of andrographolide that leads to a block
in the G0-G1 phase of the cell cycle, bringing about the
anti-cancer activity.
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